secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-010191
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained
-------------------------------------------------------------------------------

- Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.
- OLE trial: pooled PANSS total score decreased 18.6 points (p≤0.0001) at 1 year; well tolerated with no single side effect >5%.
- Registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia expected to initiate mid-2025.
- Full OLE data including vocal and blood biomarkers due Q2 2025; NDA submission targeted Q4 2026.
- Completed public follow-on offering with gross proceeds of ~$18.0M in December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/0001437749-25-010191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925010191/rvph20250325_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-010191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer